Lung Cancer | Specialty

Expert Examines Immunotherapy Potential in Small Cell Lung Cancer

May 12th 2016

David P. Carbone, MD, PhD, shares insight on the CheckMate-032 and KEYNOTE-028 trials and others that are exploring immunotherapy in patients with small cell lung cancer.

More Advances Anticipated in Fast-Moving Lung Adenocarcinoma Field

May 6th 2016

After a decade of advances in the diagnosis and treatment of patients with adenocarcinoma non-small cell lung cancer, the prospect for further progress remains bright.

Clovis Ends Development of Rociletinib in Lung Cancer

May 6th 2016

Clovis has stopped clinical development of rociletinib, its once promising EGFR inhibitor for the treatment of patients with EGFR T790M–mutated non–small cell lung cancer.

CHMP Grants Positive Opinion for Bevacizumab/Erlotinib Combo in NSCLC

April 29th 2016

The Committee for Medicinal Products for Human Use has recommended the first-line approval of bevacizumab (Avastin) in combination with erlotinib (Tarceva) for patients with advanced or metastatic EGFR-mutant non–small cell lung cancer.

CHMP Recommends Approval of Everolimus for GI, Lung NETs

April 29th 2016

Everolimus (Afinitor) has received a positive recommendation from the EMA’s Committee for Medicinal Products for Human Use as a treatment for patients with progressive, unresectable or metastatic, well-differentiated nonfunctional gastrointestinal or lung neuroendocrine tumors.

Sequencing Agents in Metastatic Colorectal Cancer

April 28th 2016

Use of VEGF-Targeted Tyrosine Kinase Inhibitors

April 28th 2016

Patient Selection for Aflibercept in Advanced CRC

April 28th 2016

The Hunt for Predictive Biomarkers

April 28th 2016

Ramucirumab Data for Colorectal Cancer: Where Does it Fit In

April 28th 2016

What Is Clinically Meaningful?

April 28th 2016

Reviewing Ramucirumab Data for Lung Cancer

April 28th 2016

Trials of Ramucirumab in Gastric Cancer

April 28th 2016

Patient Selection for Antiangiogenic Therapy

April 28th 2016

Bevacizumab Use in Angiogenesis Clinical Practice

April 28th 2016

How Does Antiangiogenic Therapy Work?

April 28th 2016

Interplay Between Angiogenesis and Immunity

April 28th 2016

Angiogenesis in Tumor Growth and Metastasis

April 28th 2016

The Picture Is Finally Changing in Squamous NSCLC

April 22nd 2016

Treatment options for patients with squamous non–small cell lung cancer are expanding rapidly yet the field is still lagging in targeted therapies and curative strategies

Sangeetha Palakurthi on Strategies for Managing Resistance to Osimertinib in Patients With NSCLC

April 21st 2016

Sangeetha Palakurthi, PhD, head of the Cancer Biology and Pharmacology Group at the Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, discusses a study that utilized non–small cell lung cancer (NSCLC) patient-derived xenografts from patients on osimertinib (AZD9291) clinical trials to further refine therapeutic strategies.